Evaluation of Bevacizumab, Temozolomide, and Irinotecan in Pediatric Refractory/Relapsed Neuroblastoma: A Randomized Phase IIb Trial
- Trial ID
- 2024-518931-12-00
- Protocol
- RG_11-087
- Sponsor
- The University Of Birmingham
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to assess the efficacy of adding **bevacizumab** to a chemotherapy regimen consisting of **temozolomide** with or without **irinotecan** or **topotecan** in children with relapsed or refractory **neuroblastoma**. This evaluation is clinically significant as it aims to determine whether the addition of bevacizumab enhances the therapeutic activity of the chemotherapy regimen, potentially leading to improved treatment outcomes for this challenging pediatric cancer.
Secondary objectives include evaluating the safety of these therapy regimens and comparing how the combinations influence the frequency of relapses and prolong the survival of treated patients. These objectives are crucial for understanding the overall benefit-risk profile of the treatment combinations, which is essential for optimizing therapeutic strategies in this patient population.
Participants
The clinical trial involves a total of **89 participants** diagnosed with **neuroblastoma**, specifically targeting children with relapsed or refractory forms of the disease. The study population includes both male and female subjects, aged between **1 to 21 years**. Participants were selected based on specific inclusion criteria, such as having histologically proven neuroblastoma according to the International Neuroblastoma Staging System, adequate cardiac and lung function, and measurable disease by cross-sectional imaging or evaluable disease. The trial also considers lifestyle factors, requiring females of childbearing potential to have a negative pregnancy test and all sexually active participants to use appropriate contraception. The trial population is characterized by a vulnerable group, given the age range and the nature of the disease. Participants must have a performance status of Lansky or Karnofsky ≥ 50% or ECOG ≤ 3, and adequate bone marrow, renal, and liver function. The selection process ensures that only those meeting these stringent health criteria are included, thereby maintaining the integrity and safety of the trial.
Plans and Procedures
The clinical trial is designed to evaluate the efficacy of adding **bevacizumab** to a chemotherapy regimen consisting of **temozolomide**, **irinotecan**, and **topotecan** in children with relapsed or refractory **neuroblastoma**. This is a randomized, phase IIb trial with a double-blind, controlled design. The trial is expected to last until February 2026, with recruitment starting in January 2025. Participants will be involved for a maximum treatment period of 24 months, depending on their response to the treatment and any adverse events experienced.
The study visits are structured as follows: an initial inclusion (screening) visit will determine eligibility based on criteria such as histologically proven neuroblastoma, adequate cardiac and lung function, and measurable disease. Following randomization, participants will undergo regular follow-up visits to monitor treatment response and safety. These visits will include assessments of primary endpoints, such as best response and progression-free survival, and secondary endpoints, including safety, event-free survival, and overall survival. The end-of-study visit will conclude the participant's involvement, assessing the overall outcomes and any long-term effects of the treatment.
Participants may be withdrawn from the study early if they experience unacceptable toxicity, disease progression, or if they withdraw consent. The trial will adhere to strict eligibility criteria, including age between 1 and 21 years, informed consent, and specific performance status requirements. The study aims to provide valuable insights into the potential benefits of combining bevacizumab with established chemotherapy agents in treating neuroblastoma, with a focus on improving progression-free and overall survival rates.
Treatment
The clinical trial involves the administration of several experimental medications, each with specific pharmaceutical forms, dosages, and routes of administration. **Temozolomide** is utilized in this study in the form of a hard capsule. It is administered orally with a maximum daily dose of 200 mg/m² and a total maximum dose of 6000 mg/m² over a treatment period of 24 months. The active substance is of chemical origin, and the medication is not formulated for pediatric use.
**Dinutuximab Beta** is provided as a solution for infusion and is administered intravenously. The maximum daily dose is 10 mg/m², with a total maximum dose of 420 mg/m² over the same 24-month treatment period. This substance is a structurally diverse immunoglobulin and is not a pediatric formulation.
**Irinotecan** is administered as a concentrate for solution for infusion, delivered intravenously. The maximum daily dose is 50 mg/m², with a total maximum dose of 1500 mg/m² over 24 months. The active substance is of chemical origin, and the formulation is not intended for pediatric use.
**Bevacizumab** is also a concentrate for solution for infusion, administered intravenously. The maximum daily dose is 15 mg/kg, with a total maximum dose of 720 mg/kg over the 24-month period. The active substance is a protein of other origin, and the formulation is not pediatric.
**Cyclophosphamide** is provided as a powder for solution for injection or infusion, administered intravenously. The maximum daily dose is 250 mg/m², with a total maximum dose of 5000 mg/m² over the 24-month treatment period. The active substance is of chemical origin, and the formulation is not pediatric.
**Topotecan** is administered as a concentrate for solution for infusion, delivered intravenously. The maximum daily dose is 0.75 mg/m², with a total maximum dose of 22.5 mg/m² over 24 months. The active substance is of chemical origin, and the formulation is not intended for pediatric use.
Throughout the trial, participant compliance with the dosing schedules is monitored to ensure adherence to the treatment regimen. The study does not include any non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatment. The trial aims to evaluate the efficacy of these medications in children with relapsed or refractory neuroblastoma.
Efficacy
The efficacy of the clinical trial will be assessed using several primary and secondary endpoints. The primary endpoints include the best response, defined as Complete Response (CR) or Partial Response (PR) at any time during the first six cycles of trial treatment, and **Progression-Free Survival (PFS)** specifically for the bevacizumab part of the study. Secondary endpoints will evaluate the safety of the regimens through the incidence and severity of Adverse Events (AE), as well as additional measures such as PFS, Event-Free Survival (EFS), and Overall Survival (OS).
These efficacy parameters will be measured and collected at specified intervals throughout the trial. The best response will be assessed according to the criteria established by Brodeur et al. (1988), while PFS, EFS, and OS will be monitored to provide comprehensive insights into the treatment's impact on disease progression and patient survival. The trial is designed to rigorously evaluate the therapeutic activity of bevacizumab when added to a chemotherapy regimen in children with relapsed or refractory neuroblastoma, as well as the potential enhancement of chemotherapy efficacy with the addition of irinotecan or topotecan to temozolomide.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Histologically proven neuroblastoma as per International Neuroblastoma Staging System (INSS) (Brodeur et al. 1988) definition
- Relapsed or refractory neuroblastoma o Relapsed: any relapsed or progressed high-risk neuroblastoma o Refractory high risk disease: Lack of adequate response to frontline therapy that precludes the patient from proceeding to consolidation therapies (e.g. myeloablative chemotherapy)
- Measurable disease by cross sectional imaging (RECIST) or evaluable disease (uptake on MIBG scan with or without bone marrow histology). Patients with only bone marrow detectable disease (bone marrow aspirate or trephine) are NOT eligible for the study
- Age ≥1 to ≤21 years
- Informed consent from patient, parent or guardian
- Performance Status: o Lansky ≥ 50%, Karnofsky ≥ 50% or ECOG ≤3 o (Patients who are unable to walk because of paralysis, but who are able to sit upright unassisted in a wheelchair, will be considered ambulatory for the purpose of assessing performance score)
- Bone marrow function (prior to 72 hours of planed randomisation date): o No bone marrow disease: Platelets ≥ 75 x 109/L (unsupported for 72 hours) ANC ≥ 0.75 x 109/L (no G-CSF support for 72 hours) Haemoglobin > 7.5 g/dL (transfusions allowed) o Bone marrow disease: Platelets ≥ 50 x109/L (unsupported for 72 hours) ANC ≥0.5 x 109/L (no G-CSF for 72 hours) Haemoglobin > 7.5 g/dL (transfusions allowed) Dinutuximab beta arm only: • Bone marrow function (within 72 hours of randomisation): o No bone marrow disease: Platelets ≥75 x 109/L (unsupported for 72 hours) ANC ≥ 0.75 x109/L (no G-CSF support for 72 hours) Haemoglobin ≥ 8 g/dL (transfusions allowed) o Bone marrow disease: Platelets ≥ 50 x109/L (unsupported for 72 hours) ANC ≥ 0.5 x 109/L (no G-CSF for 72 hours) Haemoglobin ≥ 8 g/dL (transfusions allowed)
- Renal function (prior to 7 days of randomisation date):Serum creatinine ≤ 1.5 ULN for age, if higher, a calculated GFR (radioisotope or 24 hour urine calculated creatinine clearance) must be ≥ 60 ml/min/1.73 m2
- Liver function (prior to 72 hours of randomisation date): AST or ALT ≤3 ULN and total bilirubin ≤1.5 ULN. In case of liver metastases, AST or ALT ≤5 ULN and total bilirubin ≤2.5 ULN.
- Cardiac function, measured using echocardiogram prior to 4 weeks of randomisation date or 12 weeks if patient has not received anthracyclines or cardiotoxics. Shortening fraction ≥29% on echocardiogram
- Adequate lung function; no dyspnoea at rest and pulse oximetry > 94% in room air
- Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to initiation of treatment. Sexually active women of childbearing potential must agree to use acceptable and appropriate contraception during the study and for at least 6 months after the last study treatment administration. Sexually active males patients must agree to use condom during the study and for at least 6 months after the last study treatment administration.
- Availability and willingness to place a double central venous access if needed for trial treatment and supportive care in case of treatment with chemo-immunotherapy
Exclusion Criteria
- Previous treatment with temozolomide drugs
- Previous treatment with chemotherapy in combination with anti-GD2 directed therapy (“chemo-immunotherapy”) with any anti-GD2 antibody. Prior treatment with anti-GD2 directed therapy alone with/without cytokines is allowed provided a 4 week wash-out period is met
- Known hypersensitivity to: o Any study drug or component of the formulation
- Patients with mild previous hypersensitivity reactions to anti-GD2 antibodies may be included, but those with severe (or G4) hypersensitivity reactions to antiGD2 antibodies will be excluded Clinically significant neurological deficit, uncontrolled seizures or objective peripheral neuropathy (>grade 2). (Unresolved neurological deficits from previous spinal cord compression are acceptable)
- Uncontrolled infection
- Inadequate recovery from prior surgery with no ongoing ≥Grade 3 surgical complications. For core biopsies, no less than 24 hours; for open excisional biopsies, no less than 48 hours; for major surgery, no less than 2 weeks Patient less than (at point of planned date of randomisation): Two weeks from prior chemotherapy. One week from prior oral metronomic chemotherapy (i.e. oral etoposide or oral cyclophosphamide).Six weeks from prior craniospinal radiotherapy or MIBG therapy and two weeks from radiotherapy to the tumour bed. No washout is required for palliative radiotherapy Eight weeks from prior high dose chemotherapy with autologous haematopoietic stem cell rescue Three months from prior allogeneic stem cell transplant, no ongoing treatment with immunosuppressive agents and no signs of ≥grade 2 acute graft versus host disease 14 days or 5 half-lives (whichever occurs later) from last administration of an IMP in an IMP-trial. 14 days or 5 half-lives (whichever occurs later) from last administration of any other biological/targeted anticancer agent
- Bleeding metastases (Patients with CNS metastases can be enrolled as long as the metastases are not bleeding) Pregnant or lactating patient Any uncontrolled medical condition that poses an additional risk to the patient Low probability of treatment compliance
- History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation) (Bevacizumab randomisation only)
- History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to study enrolment (Bevacizumab randomisation only)
- Current chronic intestinal inflammatory disease/bowel obstruction (Bevacizumab randomisation only)
- Known intolerance to galactose and fructose, lactase deficiency, and/or defect of absorption of galactose and fructose (Bevacizumab randomisation only)
- Pregnant or lactating patient
- Any uncontrolled medical condition that poses an additional risk to the patient (i.e. haemoptysis, non-healing, bone fracture, wound/ulcer)
- Low probability of treatment compliance
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Belgium | Not Recruiting | 31 Jan 2025 | 6 |
Denmark | Not Recruiting | 31 Jan 2025 | 7 |
France | Not Recruiting | 31 Jan 2025 | 65 |
The Netherlands | Not Recruiting | 31 Jan 2025 | — |
Spain | Not Recruiting | 31 Jan 2025 | 33 |
Netherlands | — | — | 11 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
TEMOZOLOMIDE | Test | — | ORAL USE | 200 | 24 | SUB10889MIG |
TEMOZOLOMIDE | Test | — | ORAL USE | 200 | 24 | SUB10889MIG |
DINUTUXIMAB BETA | Test | — | INTRAVENOUS USE | 10 | 24 | SUB174757 |
TEMOZOLOMIDE | Test | — | ORAL USE | 200 | 24 | SUB10889MIG |
IRINOTECAN | Test | — | INTRAVENOUS USE | 50 | 24 | SUB08295MIG |
TEMOZOLOMIDE | Test | — | ORAL USE | 200 | 24 | SUB10889MIG |
BEVACIZUMAB | Test | — | INTRAVENOUS USE | 15 | 24 | SUB16402MIG |
TEMOZOLOMIDE | Test | — | ORAL USE | 200 | 24 | SUB10889MIG |
CYCLOPHOSPHAMIDE | Test | — | INTRAVENOUS USE | 250 | 24 | SUB06859MIG |
TEMOZOLOMIDE | Test | — | ORAL USE | 200 | 24 | SUB10889MIG |





